Invex Therapeutics Ltd. (AU:IXC) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invex Therapeutics Ltd has announced the results of its Annual General Meeting, where several resolutions, including the adoption of the remuneration report and the election of directors, were carried, while the issuance of securities under an incentive plan was not approved. The company continues its focus on repurposing the drug Exenatide for neurological treatments, underlining its commitment to innovation in biopharmaceuticals.
For further insights into AU:IXC stock, check out TipRanks’ Stock Analysis page.